Chinese Liver Cancer Clinical Survey
- Conditions
- Primary Liver Cancer
- Registration Number
- NCT03161925
- Lead Sponsor
- Beijing Insight Science & Technology Co. Ltd.
- Brief Summary
In order to make better use of clinical resources of the real world, strengthen the standardization of PLC diagnosis and treatment, and constantly improve the academic level of liver cancer in China, we intends to launch "Chinese Liver Cancer clinical Survey" project in cancer specialized hospitals and large general hospitals and to explore the best clinical pathway of PLC multidisciplinary consultation.
- Detailed Description
Primary liver cancer (PLC) is one of the most common malignant tumors of digestive system and also a serious threat to the health and safety of Chinese people, and has caused serious economic burden to the country. Research purposes: To understand the clinical characteristics of patients with primary liver cancer (PLC) in China; To investigate the etiology and pathogenesis of PLC in China; To understand the current status of clinical treatment of PLC in China, and to analyze the gaps among these conditions and domestic treatment guidelines, industry consensus, the international treatment guidelines; To understand the different treatment options and its clinical outcomes, and to explore the best treatment options; To explore the best clinical pathway of PLC multidisciplinary consultation; To provide the basis for the development of clinical guidelines for PLC in China.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 5000
- Diagnosis of PLC after January 1,2012;
- First treatment and efficacy evaluation.
- Complicated with another primary malignant tumor and secondary liver cancer.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival 5 years Overall survival
- Secondary Outcome Measures
Name Time Method